Sign in Create account

Onesource Specialty Pharma Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: ONESOURCE BSE: 544292
₹1521.60
▼ -61.70 (-3.90%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
44/100
Moderate
Valuation
48/100
Fairly Valued
Momentum
14/100
Bearish

QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Bearish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹17,445 Cr
PE (TTM)
366.7
Industry median 36.1 (152 companies)
Price to Book
3.0
PEG (TTM)
1.4
Institutions holding %
42.57%
FII + DII, latest filed period
Piotroski Score
3
Relative return vs Nifty50, qtr %
-1.4
Relative return vs Sector, qtr %
-7.8
Free Cash Flow
₹-561 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
105.99%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
Data unavailable.
Operating Revenue Growth (TTM)
27.24%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
106.43%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
39.08%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
0.99
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.22
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
1.38
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
11.47%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
18.31%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
11.21%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-0.90%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
0.45%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
-1.27%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 3)
  • Yes Debt to equity is below 0.5 (0.22)
  • No Return on equity is 15% or more (-1.3%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (37.2% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

2 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

1 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-3.9%
Low 1506.1000 · High 1600.0000
1W return
-4.7%
Low 1506.1000 · High 1634.4000
1M return
0.2%
Low 1504.1000 · High 1657.5000
52W return
-14.9%
Low 1057.0000 · High 1925.0000
Lifetime High ₹2197.8000 (June 30, 2025)
Lifetime Low ₹1114.0000 (Jan. 29, 2026)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
1563.9
10D
1572.9
20D
1572.2
50D
1582.6
100D
1591.5
200D
1577.5

Delivery and volume

Day avg. delivery
44.5%
Week avg. delivery
52.8%
Month avg. delivery
49.6%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1542.57
Pivot
First resistance1579.03
Second resistance1636.47
Third resistance1672.93
First support1485.13
Second support1448.67
Third support1391.23
Day RSI40.8
Day MFI72.2
Day MACD0.94
Day MACD signal3.78

Beta

1M0.57
3M0.19
1Y-0.21
3Y0.32

Price change analysis

↑ 0.2%
Over 1 Month
LowHigh
1504.101657.50
↓ -7.8%
Over 3 Months
LowHigh
1478.001755.20
↑ 5.9%
Over 6 Months
LowHigh
1316.401917.80
↓ -14.9%
Over 1 Year
LowHigh
1057.001925.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 366.7 (own history: 118.7–1945.0)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹446 Cr
Net profit (June 30, 2026)
₹51 Cr
Basic EPS (June 30, 2026)
₹4.4700

Ranks #31 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter30.48%
  • Mutual funds12.98%
  • FII/FPI19.19%
  • Other DII10.40%
  • Public26.95%

Largest holders

NameCategoryShares %Shares
TENSHI PHARMACEUTICALS PRIVATE LIMITEDPromoter18.4000%21089714
KARUNA BUSINESS SOLUTIONS LLPPromoter7.0600%8090353
MOTILAL OSWAL MUTUAL FUNDPublic7.0600%8094694
AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITEDPublic4.9600%5681844
PRONOMZ VENTURES LLPPromoter2.4100%2761308

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 30.48% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 17.50% to 19.19% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 10.13% to 12.98% in Jun 2026 qtr

19 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 16 insider trades, 14 SAST, 3 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
6 Feb 2026 Tenshi Pharmaceuticals Private Limited Promoter Buy 0 ₹0
6 Feb 2026 Tenshi Pharmaceuticals Private Limited Promoter Buy 0 ₹0
6 Feb 2026 PRONOMZ VENTURES LLP Promoter group Buy 0 ₹0
6 Feb 2026 PRONOMZ VENTURES LLP Promoter group Buy 0 ₹0
6 Feb 2026 TENSHI PHARMACEUTICALS PRIVATE LIMITED Promoter Buy 0 ₹0
6 Feb 2026 TENSHI PHARMACEUTICALS PRIVATE LIMITED Promoter Buy 0 ₹0
16 Jun 2025 Pronomz Ventures LLP Promoter group Sell 0 ₹0
10 Feb 2025 Sajitha Pillai Promoter group Sell 0 ₹0
6 Feb 2025 Tenshi Pharmaceuticals Private Limited Promoter Sell 0 ₹0
6 Feb 2025 Hemalatha Pillai Promoter group Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 14 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
21 Apr 2026 NOVA GLOBAL OPPORTUNITIES FUND PCC - TOUCHSTONE Bulk Sell 1,057,902 1530.0000 NSE
21 Apr 2026 FIDELITY SECURITIES FUND: FIDELITY BLUE CHIP GROWTH FUND Bulk Buy 2,017,662 1530.0000 NSE
21 Apr 2026 AUTHUM INVESTMENT & INFRASTRUCTURE LIMITED Bulk Sell 950,000 1530.0900 NSE
21 Apr 2026 AUTHUM INVESTMENT & INFRASTRUCTURE LIMITED Bulk Buy 172,668 1556.6900 NSE
17 Nov 2025 KARUNA BUSINESS SOLUTIONS LLP Block Buy 200,000 1735.0000 NSE
17 Nov 2025 AMANSA HOLDING PRIVATE LTD. Block Sell 200,000 1735.0000 NSE
15 May 2025 MEDELLA HOLDINGS PTE. LTD. Bulk Sell 884,210 1568.0400 BSE
31 Jan 2025 TENSHI PHARMACEUTICALS PRIVATE LIMITED Bulk Sell 1,941,747 1545.0300 NSE
31 Jan 2025 TENSHI PHARMACEUTICALS PRIVATE LIMITED Bulk Sell 1,359,223 1545.0000 NSE
31 Jan 2025 PRONOMZ VENTURES LLP Bulk Sell 582,524 1545.0000 NSE

All bulk and block deals →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
24 Jul 2026 Financial Results Yes
13 May 2026 Financial Results Yes
23 Jan 2026 Financial Results Yes
11 Nov 2025 Financial Results Yes
4 Aug 2025 Financial Results Yes

Corporate Announcements

All 165 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
25 Sep 2026 Updates Onesource Specialty Pharma Limited has informed the Exchange regarding 'Allotment of ESOPs'.
25 Sep 2026 Trading Window Onesource Specialty Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
25 Sep 2026 Shareholders meeting Onesource Specialty Pharma Limited has submitted the Exchange a copy Srutinizers report and voting results for the 19th AGM held on September 23, 2026.
25 Sep 2026 AGM/EGM Onesource Specialty Pharma Ltd - 544292 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
25 Sep 2026 Insider Trading / SAST Onesource Specialty Pharma Ltd - 544292 - Closure of Trading Window
25 Sep 2026 Company Update Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
23 Sep 2026 Change in Auditors Onesource Specialty Pharma Limited has informed the Exchange regarding Change in Auditors of the company.
23 Sep 2026 Shareholders meeting Onesource Specialty Pharma Limited has informed the Exchange regarding Proceedings of 19th Annual General Meeting held on September 23, 2026
11 Sep 2026 Company Update Onesource Specialty Pharma Ltd - 544292 - General Update
11 Sep 2026 Updates Onesource Specialty Pharma Limited has informed the Exchange regarding 'Addendum to the notice of the 19th AGM scheduled to be held on September 23, 2026

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.22)
  • Strong revenue growth YoY (39.1%)

Weaknesses

  • Low Return on Equity (-1.3%)
  • Tight liquidity (Current Ratio 0.99)

Opportunities

Data unavailable.

Threats

  • PE above 35 (366.7) -- priced for continued strong execution
  • Weak interest coverage (1.4x) -- limited cushion against rising rates

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Part of: NIFTY 500, NIFTY 500

Frequently asked questions about Onesource Specialty Pharma Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.